Allied Minds will henceforth operate without a chief executive after Joseph Pignato announced his decision to resign.
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.